62 related articles for article (PubMed ID: 17921849)
1. Retrospective study on elimination delay of methotrexate in high-dose therapy of childhood acute lymphoblastic leukemia in China.
Xu W; Tang Y; Song H; Shi S; Yang S
J Pediatr Hematol Oncol; 2007 Oct; 29(10):688-93. PubMed ID: 17921849
[TBL] [Abstract][Full Text] [Related]
2. A single assessment of methotrexate levels at 42 hours permits safe administration and early discharge in children with lymphoblastic lymphoma and leukemia receiving high-dose methotrexate.
Totadri S; Srinivasan HN; Joseph LL; Boddu D; Mathew LG; John R
Pediatr Hematol Oncol; 2021 Aug; 38(5):434-443. PubMed ID: 33764242
[TBL] [Abstract][Full Text] [Related]
3. Plasma creatinine as predictor of delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia: A Danish population-based study.
Schmidt D; Kristensen K; Schroeder H; Wehner PS; Rosthøj S; Heldrup J; Damsgaard L; Schmiegelow K; Mikkelsen TS
Pediatr Blood Cancer; 2019 Jun; 66(6):e27637. PubMed ID: 30835935
[TBL] [Abstract][Full Text] [Related]
4. Is hypoalbuminemia a risk factor for high-dose methotrexate toxicity in children with acute lymphoblastic leukemia?
Barakat S; Assem H; Salama M; Mikhael N; El Chazli Y
J Egypt Natl Canc Inst; 2022 Apr; 34(1):17. PubMed ID: 35434757
[TBL] [Abstract][Full Text] [Related]
5. Effect of Body Fat on Population Pharmacokinetics of High-Dose Methotrexate in Pediatric Patients With Acute Lymphoblastic Leukemia.
Orgel E; Nabais T; Douglas C; Mittelman SD; Neely M
J Clin Pharmacol; 2021 Jun; 61(6):755-762. PubMed ID: 33314168
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia and lymphoma.
Nakano T; Kobayashi R; Matsushima S; Hori D; Yanagi M; Suzuki D; Kobayashi K
Int J Hematol; 2021 May; 113(5):744-750. PubMed ID: 33389654
[TBL] [Abstract][Full Text] [Related]
7. Impact of pre-hydration duration on high-dose methotrexate induced nephrotoxicity in childhood acute lymphoblastic leukaemia in resource constraint centers: a randomized crossover study.
Khera S; Mahajan D; Barbind K; Dhingra S
Cancer Chemother Pharmacol; 2023 Apr; 91(4):331-336. PubMed ID: 36951972
[TBL] [Abstract][Full Text] [Related]
8. [Clinical application of the simultaneous detection of methotrexate and 7-hydroxymethotrexate in the delayed elimination for pediatric acute lymphoblastic leukemia].
Luo GJ; Wang L; Hu GF; Li CB; Liu HX; Peng MT
Zhonghua Yi Xue Za Zhi; 2020 Jul; 100(25):1973-1978. PubMed ID: 32629599
[No Abstract] [Full Text] [Related]
9. [Adverse effects of high-dose methotrexate therapy].
Sun Q; Xie Y; Zhao WH; Hua Y; Wu PH; Li S; Lu XT
Zhongguo Dang Dai Er Ke Za Zhi; 2017 Jul; 19(7):781-785. PubMed ID: 28697831
[TBL] [Abstract][Full Text] [Related]
10. Safe administration of high-dose methotrexate with minimal drug level monitoring: Experience from a center in north India.
Dhingra H; Kalra M; Mahajan A
Pediatr Blood Cancer; 2020 Nov; 67(11):e28394. PubMed ID: 32813334
[TBL] [Abstract][Full Text] [Related]
11. High-Dose Methotrexate in Pediatric Acute Lymphoblastic Leukemia: Predictors of Delayed Clearance and the Effect of Increased Hydration Rate on Methotrexate Clearance.
Chen AR; Wang YM; Lin M; Kuo DJ
Cureus; 2020 Jun; 12(6):e8674. PubMed ID: 32699674
[TBL] [Abstract][Full Text] [Related]
12. Case report on hypersensitivity to methotrexate infusion in a pediatric acute lymphoblastic leukaemia patient.
Sajith M; Pawar A; Bafna V; Bartakke S
J Oncol Pharm Pract; 2020 Mar; 26(2):462-464. PubMed ID: 30961436
[TBL] [Abstract][Full Text] [Related]
13. Do intravenous fluid substitutions influence methotrexate clearance? An unanticipated impact of an intravenous sodium bicarbonate drug shortage.
Mangum R; Bernhardt MB; Cheng WS; Schafer ES; Berg SL; Foster JH
Pediatr Blood Cancer; 2020 Sep; 67(9):e28334. PubMed ID: 32608575
[TBL] [Abstract][Full Text] [Related]
14. The effect of the plasma methotrexate concentration during high-dose methotrexate therapy in childhood acute lymphoblastic leukemia.
Liao C; Nie J; Xu XJ; Zhang JY; Xu WQ; Song H; Shen HP; Shen DY; Zhao FY; Liang J; Miao J; Tang YM
Leuk Lymphoma; 2024 Jan; 65(1):91-99. PubMed ID: 37820046
[TBL] [Abstract][Full Text] [Related]
15. Genetic factors involved in delayed methotrexate elimination in children with acute lymphoblastic leukemia.
Cheng Y; Chen MH; Zhuang Q; Lin BJ; Chen YY; Yang L; Liu MB; Que WC; Qiu HQ
Pediatr Blood Cancer; 2021 May; 68(5):e28858. PubMed ID: 33501733
[TBL] [Abstract][Full Text] [Related]
16. Methotrexate concentrations and associated variability factors in high dose therapy of children with acute lymphoblastic leukemia and non-Hodgkin lymphoma.
Škorić B; Kuzmanović M; Jovanović M; Miljković B; Micić D; Jović M; Jovanović A; Vučićević K
Pediatr Hematol Oncol; 2023; 40(5):446-457. PubMed ID: 37195735
[TBL] [Abstract][Full Text] [Related]
17. Calcium Channel Blockers Possibly Delay the Elimination of Plasma Methotrexate in Patients Receiving High-Dose Methotrexate Therapy.
Inose R; Takahashi K; Nanno S; Hino M; Nagayama K
J Chemother; 2019 Feb; 31(1):30-34. PubMed ID: 30773130
[TBL] [Abstract][Full Text] [Related]
18. Serum Methotrexate Level and Side Effects of High Dose Methotrexate Infusion in Pediatric Patients with Acute Lymphoblastic Leukaemia (ALL).
Sajith M; Pawar A; Bafna V; Bartakke S; Subramanian K; Vaidya N
Indian J Hematol Blood Transfus; 2020 Jan; 36(1):51-58. PubMed ID: 32174691
[TBL] [Abstract][Full Text] [Related]
19. Hypersensitivity reaction to high-dose methotrexate and methotrexate-induced acral erythema in a child with acute lymphoblastic leukemia.
Akaihata M; Miyata K; Shimomura Y; Hori T; Okumura A
Int J Clin Pharmacol Ther; 2022 Jun; 60(6):264-268. PubMed ID: 35343432
[TBL] [Abstract][Full Text] [Related]
20. Predicting delayed methotrexate elimination in pediatric acute lymphoblastic leukemia patients: an innovative web-based machine learning tool developed through a multicenter, retrospective analysis.
Jian C; Chen S; Wang Z; Zhou Y; Zhang Y; Li Z; Jian J; Wang T; Xiang T; Wang X; Jia Y; Wang H; Gong J
BMC Med Inform Decis Mak; 2023 Aug; 23(1):148. PubMed ID: 37537590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
